Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 2

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1
Chunk 2
---
 the use of nonsteroidal anti-inflammatory drugs (or “NSAIDs”) which are
approved to alleviate pain and inflammation but present the potential for side effects relating to gastrointestinal, kidney, and liver
damage and do not halt or slow joint degeneration. The Company offers an alternative to traditional treatments that only address the
symptoms of the affliction. our Spryng® product addresses the affliction, loss of synovial fluid and/or the deterioration
of joint cartilage, rather than treating just the symptoms and, to the best of our knowledge, has elicited minimal adverse side effects
in dogs and horses. Spryng®-treated dogs and horses have shown an increase in activity even after they no longer are receiving pain
medication or other treatments. Other treatments for osteoarthritis include steroid and/or hyaluronic acid injections, which are used
for treating pain, inflammation and/or joint lubrication, but can be slow acting and/or short lasting.

We
believe Spryng® is an optimal solution to safely improve joint function in animals for several reasons:

    ●
    Spryng®
    addresses the underlying problems which relate to deterioration of cartilage causing pain and inflammation. Spryng®
    mimics the composition and mechanical properties of extracellular matrix and assists in promoting a constructive restoration of diseased
    synovial tissue to improve the biomechanics and mechanical homeostasis of the joint.

    ●
    Spryng®
    is easily administered with the standard intra-articular injection technique. Multiple joints can be treated simultaneously.

    ●
    Case
    studies indicate many dogs and horses have long-lasting multi-month improvement in lameness after having been treated with Spryng®

    ●
    After
    receiving a Spryng® injection, many canines are able to discontinue the use of NSAID’s, eliminating the risk
    of negative side effects.

    ●
    Spryng®
    is an effective and economical solution for treating osteoarthritis. A single injection of Spryng® is approximately
    $600 to $900 per joint and typically lasts for at least 12 months.

Historically,
drug sales represent up to 30% of revenues at a typical veterinary practice (Veterinary Practice News). Revenues and margins at veterinary
practices are being eroded because online, big-box, and traditional pharmacies have recently started filling veterinary prescriptions.
Veterinary practices are looking for ways to